HitGen Inc. announced that it has entered into a research agreement with Nitrase Therapeutics, Inc. (Nitrase), a biopharmaceutical company deploying its NITROME platform to build a pipeline of therapies targeting nitrases, which is a new class of enzymes discovered by Nitrase that are involved in a broad variety of diseases.
HitGen inks research collaboration with Daewoong Pharma focused on DNA-encoded library based drug discovery
Vernalis Research, a fully owned subsidiary of Chinese firm HitGen Inc., and US-based Unison Medicines Inc. have announced a research collaboration on an undisclosed bacterial target.
Vernalis Research (Vernalis), a fully owned subsidiary of HitGen Inc., and Unison Medicines Inc. (Unison), a discovery stage pharmaceutical company, have announced a research collaboration on an undisclosed bacterial target.